Eli Lilly has launched its blockbuster diabetes and weight-loss drug Mounjaro in India following approval from the country's ...

(Reuters) -Eli Lilly plans to launch its blockbuster diabetes and weight-loss drug, Mounjaro, in countries like China, India, ...

Once-a-weekly, prescription-based medicine, Mounjaro is a single molecule that selectively binds to and activates both GIP ...

Congress authorized the FDA to determine whether a drug is “in shortage in the United States.” The FDA’s determination of a drug shortage ...

Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...

A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are ...

Eli Lilly is set to launch its popular weight-loss drug in emerging markets, including India, Brazil, and Mexico, by mid-2025 ...

Danish drugmaker Novo Nordisk said Wednesday that it will drop prices 23% for all doses of Wegovy. The new monthly price of ...

Eli Lilly’s rising fortunes tied to its weight loss and diabetes drugs led to a nine-figure payday for its top executive.

Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Eli Lilly launches Mounjaro in India following drug regulator approval, targeting diabetes and weight-loss in a rapidly ...